Article

NCCN 2010: Dr. David Pfister, Memorial Sloan-Kettering Cancer Center

David G. Pfister, MD of the Memorial Sloan-Kettering Cancer Center speaks about HPV and the Risk of Cancer at the 15th Annual NCCN Conference in Hollywood, FL March, 2010.

Related Videos
Shawn Kwatra, MD: Making the Connection Between Prurigo Nodularis, Atopic Dermatitis, and Itch
Will Herrington, MBBS, MD, MA: Empagliflozin Follow-up Data Informs Clinical Care for CKD
Jennifer Lai Yee, MD, PhD, MPH: Honing in on Sparsentan’s Benefit in Genetic FSGS
Highlighting Recent Therapies for Dermatologists, with James Del Rosso, DO
Ladan Zand, MD: Obinutuzumab Promising Option for Refractory, Primary FSGS
Rahul N. Khurana, MD: Phase 1 Results on Vamikibart for Uveitic Macular Edema | Image Credit: Northern California Retina Vitreous Associates
Sunir J. Garg, MD: | Image Credit: Wills Eye Hospital
James Del Rosso, DO: Discussing What’s New in the Medicine Chest for Dermatologists
What to Look Forward To at the Fall Clinical Dermatology Conference, with Raj Chovatiya, MD, PhD
Related Content
F. Perry Wilson, MD | Credit: Yale Medicine
October 25th 2024

KAT-AKI: Tailored EHR Alerts Fail to Improve AKI Management in Hospitalized Patients

Patrick Campbell
default thumbnail for Don't Miss a Beat podcast.
September 2nd 2024

Don't Miss a Beat: Finerenone's Role in Heart Failure from ESC Congress Data

Muthiah Vaduganathan, MD, MPH Stephen Greene, MD
New Phase 3b Findings Suggest Lebrikizumab Improved Skin, Itch for Atopic Dermatitis
October 25th 2024

New Phase 3b Findings Suggest Lebrikizumab Improved Skin, Itch for Atopic Dermatitis

Tim Smith
Default thumbnail for Diabetes Dialogue, featuring podcast logo and headshots of hosts.
August 21st 2024

Diabetes Dialogue: Sotagliflozin for T1D and Other ADCES 2024 Highlights

Diana Isaacs, PharmD, BCPS, BCACP, BC-ADM, CDCES Natalie Bellini, DNP, FNP-BC, BC-ADM, CDCE
Finnian McCausland, MBBCh | Credit: Mass General Brigham
October 25th 2024

Finerenone Use Reduces UACR, New-Onset Macroalbuminuria in Heart Failure Patients

Patrick Campbell
Long-Term Tralokinumab Safe, Effective After 6 Years for Atopic Dermatitis
October 25th 2024

Long-Term Tralokinumab Safe, Effective After 6 Years for Atopic Dermatitis

Tim Smith
© 2024 MJH Life Sciences

All rights reserved.